Glaxosmithkline | GSK - Selling And Administration Expenses


Glaxosmithkline reported GBP3.56B in Selling and Administration Expenses for its fiscal quarter ending in December of 2025.





Selling And Administration Expenses Change Date
AbbVie USD 3.58B 316M Mar/2026
Amgen USD 1.58B 354M Mar/2026
AstraZeneca USD 5.06B 455M Mar/2026
Aurora Cannabis CAD 40.62M 1.17M Dec/2025
Bausch Health Companies USD 813M 12M Mar/2026
Bristol-Myers Squibb USD 1.62B 564M Mar/2026
Canopy Growth CAD 28.9M 636K Dec/2025
Corcept Therapeutics USD 128.04M 13.3M Mar/2026
Drreddys Laboratories INR 26.92B 3.74B Dec/2025
Eli Lilly USD 2.93B 198M Mar/2026
GlaxoSmithKline GBP 2.12B 558M Mar/2026
Glaxosmithkline GBP 3.56B 650.29M Dec/2025
J&J USD 6.03B 719M Mar/2026
Merck USD 2.67B 180M Mar/2026
Novartis USD 3.14B 296M Mar/2026
Pacira USD 83.88M 7.99M Mar/2026
Perrigo USD 267.3M 11.4M Mar/2026
Pfizer USD 2.92B 1.16B Mar/2026
Phibro Animal Health USD 78.32M 10.24M Dec/2025
Prestige Brands USD 30.28M 606K Mar/2026
Roche Holding CHF 7.28B 3.99B Dec/2025
Sanofi EUR 2.33B 419M Mar/2026
Supernus Pharmaceuticals USD 118.23M 4.16M Mar/2026
Takeda JPY 292B 9.21B Mar/2026
Teva Pharmaceutical Industries USD 1000M 120M Mar/2026
Zoetis USD 588M 31M Mar/2026